|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||47.33 - 50.22|
|52 Week Range||31.10 - 53.95|
|Beta (3Y Monthly)||0.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2019 - Mar 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||57.42|
A market correction in the fourth quarter, spurred by a number of global macroeconomic concerns and rising interest rates ended up having a negative impact on the markets and many hedge funds as a result. The stocks of smaller companies were especially hard hit during this time as investors fled to investments seen as being […]
MORRISVILLE, N.C., Dec. 10, 2018 -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that John M. Dineen has.
A Chicago real estate investment firm has followed through on the acquisition of a new office building in Perimeter Park.
PRA Health stock broke out Thursday amid a broad boost for medical research stocks. Medical research stocks are benefiting from inflows into biotechs.
Syneos Health™ (SYNH), the only fully integrated biopharmaceutical solutions organization, today released a trends forecast outlining critical shifts and the underlying dynamics that will shape biopharmaceutical decision making in 2019. “In 2019, healthcare marketplace dynamics will demand heightened agility and responsiveness when it comes to biopharmaceutical decision making,” said Alistair Macdonald, Chief Executive Officer of Syneos Health. Syneos Health harnessed the knowledge and experience of the Company’s industry-leading subject matter experts across the clinical and commercial spectrum to generate 10-macro trends and 40 themes for 2019.
Stocks with market capitalization between $2B and $10B, such as Syneos Health Inc (NASDAQ:SYNH) with a size of US$5.0b, do not attract as much attention from the investing community as Read More...
The latest earnings reports from leading medical company Syneos Health confirmed an acceleration in growth, as the stock quickly climbs toward a new high.
Syneos Health (SYNH) delivered earnings and revenue surprises of 10.29% and 0.44%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Raleigh, North Carolina-based company said it had a loss of 10 cents. Earnings, adjusted for one-time gains and costs, came to 75 cents per share. The results exceeded Wall Street ...
Highlights GAAP total revenue of $1.11 billion and $3.24 billion for the three and nine months ended September 30, 2018, respectively. Combined Company ASC 606 adjusted service.
RALEIGH, N.C., Nov. 05, 2018 -- Syneos HealthTM (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research.
Award Season Wins Include Industry Recognition for Digital, Print, Video and Social Media Campaigns COLUMBUS, Ohio, Oct. 25, 2018 -- GSW, a Syneos HealthTM Company and.
RALEIGH, N.C., Oct. 19, 2018 -- Syneos HealthTM (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a Contract Research Organization.
RALEIGH, N.C., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Syneos HealthTM (SYNH), the only fully integrated biopharmaceutical solutions organization, today released a study providing real-world patient insights into the effectiveness of digital advertising to speed clinical trial recruitment. Research highlights of the study, which was conducted by the Company’s Communications business, will be presented at 2:30 p.m. today at Digital Pharma East in Philadelphia, PA. The study, conducted online with 432 patients in the United States with epilepsy and migraine – two conditions with active late-phase pipelines – aimed to help digital marketers better understand patient perceptions surrounding online clinical trial advertising.
How far off is Syneos Health Inc (NASDAQ:SYNH) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock isRead More...